Retension Pharmaceuticals (NASDAQ:RTSN) CEO Eric Keller Acquires 20,800 Shares of Stock

Retension Pharmaceuticals, Inc. (NASDAQ:RTSN) CEO Eric Keller bought 20,800 shares of Retension Pharmaceuticals stock in a transaction that occurred on Tuesday, October 13th. The shares were bought at an average cost of $12.00 per share, with a total value of $249,600.00. Following the acquisition, the chief executive officer directly owned 423,377 shares in the company, valued at $5,080,524. This trade represents a 5.17% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Retension Pharmaceuticals Stock Up 2.7%

Shares of RTSN opened at $11.63 on Wednesday. Retension Pharmaceuticals, Inc. has a 52 week low of $9.66 and a 52 week high of $12.50.

Retension Pharmaceuticals Company Profile

We are a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Our product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (“PDE-5”) inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. While first-generation PDE-5 inhibitors, such as Viagra (sildenafil), were originally studied in cardiovascular indications such as hypertension and angina, we believe they did not have adequate bioavailability and tissue penetration to impact the smooth muscle cells of the central vascular and cardiac tissues and thus failed to achieve clinically meaningful reductions in blood pressure.